Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
A number of other research firms have also recently issued reports on RXRX. Morgan Stanley cut their target price on shares of Recursion Pharmaceuticals from $5.90 to $5.60 and set an “equal weight” rating for the company in a research note on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of Recursion Pharmaceuticals from $10.00 to $7.00 and set an “overweight” rating for the company in a report on Monday, November 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $7.52.
Check Out Our Latest Analysis on RXRX
Recursion Pharmaceuticals Trading Down 10.1%
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.22) EPS for the quarter, hitting analysts’ consensus estimates of ($0.22). Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. The firm had revenue of $18.55 million during the quarter, compared to analysts’ expectations of $14.81 million. During the same period in the previous year, the business posted ($0.36) earnings per share. Equities analysts forecast that Recursion Pharmaceuticals will post -0.89 earnings per share for the current year.
Insider Buying and Selling
In other Recursion Pharmaceuticals news, Director Robert Hershberg sold 25,000 shares of the company’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the transaction, the director directly owned 162,156 shares of the company’s stock, valued at $810,780. This represents a 13.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the transaction, the chief executive officer directly owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 167,408 shares of company stock valued at $701,276. Insiders own 6.65% of the company’s stock.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of institutional investors have recently modified their holdings of RXRX. American Century Companies Inc. boosted its position in shares of Recursion Pharmaceuticals by 46.0% in the third quarter. American Century Companies Inc. now owns 593,856 shares of the company’s stock valued at $2,453,000 after acquiring an additional 187,082 shares during the period. PCM Encore LLC bought a new position in Recursion Pharmaceuticals during the third quarter worth about $98,000. Liontrust Investment Partners LLP bought a new position in Recursion Pharmaceuticals during the third quarter worth about $375,000. Jump Financial LLC increased its position in Recursion Pharmaceuticals by 145.0% during the third quarter. Jump Financial LLC now owns 2,497,200 shares of the company’s stock worth $10,313,000 after acquiring an additional 1,478,027 shares during the period. Finally, First Trust Advisors LP raised its stake in Recursion Pharmaceuticals by 16.8% in the 3rd quarter. First Trust Advisors LP now owns 3,551,885 shares of the company’s stock worth $14,669,000 after purchasing an additional 510,056 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
